SAB Biotherapeutics, Inc.
SABS
$3.94
-$0.21-5.06%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 114.70K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 114.70K |
| Cost of Revenue | 32.18M | 489.90K | -6.98M | 7.66M | 28.58M |
| Gross Profit | -32.18M | -489.90K | 6.98M | -7.66M | -28.46M |
| SG&A Expenses | 6.04M | 3.71M | 2.74M | 3.11M | 3.17M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.77M | 12.68M | 9.73M | 10.77M | 10.12M |
| Operating Income | -15.77M | -12.68M | -9.73M | -10.77M | -10.01M |
| Income Before Tax | -16.86M | 45.45M | -10.11M | -5.20M | -11.39M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.86M | 45.45M | -10.11M | -5.20M | -11.39M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.86M | 45.45M | -10.11M | -5.20M | -11.39M |
| EBIT | -15.77M | -12.68M | -9.73M | -10.77M | -10.01M |
| EBITDA | -15.01M | -11.91M | -8.96M | -9.99M | -9.22M |
| EPS Basic | -0.06 | 0.50 | 0.75 | -0.56 | -1.23 |
| Normalized Basic EPS | -0.22 | 2.66 | -0.68 | -0.35 | -0.77 |
| EPS Diluted | -0.25 | -0.21 | 0.75 | -0.56 | -1.23 |
| Normalized Diluted EPS | -0.22 | 0.36 | -0.68 | -0.35 | -0.77 |
| Average Basic Shares Outstanding | 48.00M | 10.66M | 9.30M | 9.29M | 9.29M |
| Average Diluted Shares Outstanding | 48.00M | 77.86M | 9.30M | 9.29M | 9.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |